DUSP7 Knockout HCT 116 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population with targeted disruption of the DUSP7 gene in the HCT 116 human colorectal carcinoma background. This polyclonal knockout model provides a heterogeneous pool of gene-edited cells, enabling robust analysis of DUSP7-dependent signaling dynamics without clonal selection bias.
The parental HCT 116 cell line is an extensively characterized epithelial colorectal carcinoma model harboring activating mutations in KRAS (G13D) and PIK3CA, which drive constitutive MAPK/ERK and PI3K/AKT pathway activation. Such genetic alterations make HCT 116 cells particularly suited for investigating oncogenic signaling networks and therapeutic resistance mechanisms relevant to colorectal cancer.
DUSP7 encodes a dual-specificity MAP kinase phosphatase that serves as a critical negative-feedback regulator of MAPK signaling. It directly dephosphorylates conserved threonine and tyrosine residues in the activation loops of ERK1/2 and JNK1/2, thereby inactivating these kinases and attenuating downstream pathways. Upstream, DUSP7 expression is induced by growth factor stimulation (e.g., EGF, FGF) and cellular stress, while its activity modulates downstream effectors such as the transcription factors c-Fos, c-Jun, and ELK1. In the canonical RAS?CRAF?CMEK?CERK cascade, DUSP7 provides phosphatase-mediated signal termination, shaping the amplitude and duration of pathway output.
In the context of HCT 116 cells, where oncogenic KRAS sustains chronic ERK activation, disruption of DUSP7 removes a key brake on MAPK signaling. This loss-of-function model is poised to reveal hyperactivation of ERK/JNK pathways, potentiation of downstream transcriptional programs, and altered cellular phenotypes including proliferation and survival. Consequently, these polyclonal knockout cells are a powerful tool to dissect feedback control mechanisms that may influence tumor progression and response to targeted therapies.
Researchers can employ this model to investigate dynamic MAPK signaling through western blotting for phospho-ERK and phospho-JNK, RT-qPCR profiling of target genes such as FOS and JUN, or luciferase-based pathway reporter assays. Co-immunoprecipitation studies can further probe DUSP7 interactions with ERK1/2. The cells are also suitable for functional assays including proliferation, apoptosis, and drug sensitivity testing, offering valuable insights into DUSP7??s role in colorectal cancer biology and therapy resistance. For additional technical specifications or batch-specific validation data, please contact Ascent Research.
